About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Bilateral Percutaneous Nephrolithomy

Clinicaltrials.gov identifier NCT03924362

Recruitment Status Recruiting

First Posted April 23, 2019

Last update posted April 29, 2021

Study Description

Brief summary:

The purpose of this study is to determine the effective regimen for definitive surgical therapy of bilateral kidney stones. It is unknown whether patients who undergo simultaneous bilateral percutaneous nephrolithotomy (PCNL) experience improved post-operative outcomes compared to patients who have staged unilateral procedures.

  • Condition or Disease:Nephrolithiasis of Both Kidneys
  • Intervention/Treatment: Procedure: PCNL
  • Phase: N/A
Detailed Description

Purpose: The aim of this research is to determine an effective regimen for definitive surgical therapy of bilateral kidney stones. It is unknown whether patients who undergo simultaneous bilateral percutaneous nephrolithotomy (PCNL) experience improved post-operative outcomes compared to patients who have staged unilateral procedures. Hypothesis and Justification The gold standard for surgical management of large kidney stones is percutaneous nephrolithotomy (PCNL). A large renal stone burden has been defined as >20mm. In addition, PCNL has improved stone-free rates for lower pole calculi >10mm compared to alternative treatments. Guidelines encourage removal of staghorn calculi for surgical candidates (Assimos et al., 2016). Patients with bilateral large stone burdens have been managed with one of two general options: (i) a single procedure in which both kidneys are operated upon or (ii) two separate procedures in which only one kidney is addressed per procedure. However, there are no prospectively performed peer-reviewed studies directly comparing the two practices. The investigators seek to determine whether there is a significant difference in patient outcomes based on the surgical regimen chosen. The investigators hypothesize that in comparison to unilateral PCNL (U-PCNL), simultaneous bilateral PCNL (SB-PCNL) under one anesthetic results in comparable 1. stone free rates 2. re-intervention rates for residual stones and 3. perioperative complication rates Objectives The objectives are: 1. To provide clinical data on outcomes following simultaneous bilateral and staged percutaneous nephrolithotomy for renal and ureteral calculi 2. To determine patient preference with respect to simultaneous versus staged PCNL Research Design This study will be a prospective, non-randomized, multi-centre, non-blinded trial. Participants will be accrued through the Vancouver General Hospital Stone Center who have been referred for bilateral stones or have been seen in consultation for bilateral stones at the Department of Urologic Sciences and are scheduled for a percutaneous nephrolithotomy (PCNL). Consent forms and Letters of Introduction outlining the study will be given to patients by a research coordinator once the decision is made to book surgery. Patients will have at least 24 hours to decide to participate. Patients will receive surgical management for their stones in the form of PCNL. A computed tomography (CT) scan of the kidneys will be performed post-operatively by week 6 to determine if any residual stone fragments are present. Patients will be seen in follow up at 3 months in clinic after undergoing a follow up CT KUB, renal ultrasound, or KUB as necessary to evaluate stone clearance.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 92 participants
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Patients will be managed either with simultaneous bilateral procedures or staged unilateral procedures based on surgeon's routine practice pattern. Additional surgical interventional will be dependent on initial patient stone-free outcomes.
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Prospective Trial of Feasibility and Efficacy of Simultaneous Bilateral Percutaneous Nephrolithotomy
  • Actual Study Start Date: September 2019
  • Estimated Primary Completion Date: December 2021
  • Estimated Study Completion Date: December 2021
Arms and interventions
Arm Intervention/treatment
Active Comparator: Simultaneous Bilateral PCNL
Patients undergo simultaneous bilateral PCNL.
Procedure: PCNL
Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.
Active Comparator: Unilateral PCNL
Patients undergoing unilateral staged PCNL.
Procedure: PCNL
Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.
Outcome Measures
  • Primary Outcome Measures: 1. Stone Free Rates Measured using Chi-Square analysis. [ Time Frame: 3 months. ]
    Rate of clearance of kidney stones following the procedure.
  • 2. Number of Participants with Repeat procedures [ Time Frame: 3 months. ]
    Number of Participants requiring repeat surgical procedures for residual stones following initial treatment.
  • Secondary Outcome Measures: 1. Length of hospital stay [ Time Frame: 3 months. ]
    Hospital stay for simultaneous bilateral versus staged PCNL.
  • 2. Number of Participants with Complications [ Time Frame: 3 months. ]
    Number of participants with perioperative complication and rates for each procedure.
  • 3. Patient Quality of Life [ Time Frame: 3 months. ]
    Quality of life assessment comparing the two different procedures will be conducted with the Wisconsin Stone Quality of Life questionnaire (WISQOL). WISQOL is a disease-specific, health-related quality of life measure designed for patients who form kidney stones. This questionnaire has 4 different domains: social-domain 1, emotional-domain 2, stone related-domain 3 and vitality-domain 4. In the questionnaire, patients are to answer between 1 (Very true) to 5 (Not true at all). 1 is the worst outcome, and 5 is the best outcome.
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

All subjects with a clinical diagnosis of struvite calculi will potentially be included.
Specific inclusion criteria include the following:

1. Age >18 years

2. Any patient with bilateral stone burden eligible and appropriate for PCNL procedure

3. Medically fit for definitive surgical management of stone.

Exclusion Criteria:

Patients with any of the following characteristics will not be eligible for the present
study:

1. Those with medical comorbidities preventing them from safely undergoing definitive
surgical therapy.

2. Patients who are unable to provide informed consent.

3. Patients who are planned for alternative procedures (ureteroscopy, extracorporeal
shock wave lithotripsy)

4. Anyone who is unable to give their informed consent

5. Anyone under the age of 19

6. Anyone who, in the opinion of the PI, is unfit or unsuitable to participate in the
study

Contacts and Locations
Contacts

Contact: Victor Wong 604-875-4111 ext 62421 kfvwong@alumni.ubc.ca

Locations

Canada, British Columbia
University of British Columbia
Vancouver

Sponsors and Collaborators

University of British Columbia

Investigators

Principal Investigator: Ben Chew, MD University of British Columbia, Associate Professor

More Information